Sjögren's Syndrome: Diagnosis and Therapeutics provides a thorough, multisystemic overview of the clinical manifestations of Sjögren's Syndrome. It contains chapters pertinent across the range of medical specialties that may encounter Sjögren's Syndrome cases. Chapters are specialty-specific, for easy reference by the relevant medical specialist.
In addition to being a diagnostic guide, Sjögren's Syndrome: Diagnosis and Therapeutics includes a section on prognosis and outcomes of Sjögren's Syndrome patients and provides an exhaustive therapeutic update, focused on new agents and experimental techniques. The inclusion of diagnostic/therapeutic algorithms illustrates the text with clinical photographs of the main organs involved and helps the reader to make guided diagnostic and therapeutic decisions through decision-based algorithms.

Autorentext
Manuel Ramos Casals, MD, PhD is a Consultant of the Department of Systemic Autoimmune Diseases, Hospital Clínic, Barcelona, Head of the "Josep Font" Laboratory of Autoimmune Diseases of the IDIBAPS, Hospital Clinic, Barcelona and Assistant Professor, Department of Medicine, University of Barcelona, Barcelona, Spain. He has published more than 100 original articles focused on Sjögren's syndrome and related conditions, has edited 6 books on systemic autoimmune diseases and has received several national grants to investigate autoimmune diseases. John H. Stone, MD, MPH is Clinical Director of Rheumatology, Harvard Medical School, Boston, MA, USA and the Chairman of the International Network for the Study of the Systemic Vasculitides (INSSYS). Dr Stone's research interests relate to translational investigations in systemic vasculitis. He has directed two multicenter clinical trials in Wegener's granulomatosis and antineutrophil cytoplasmic antibody-associated vasculitis, the Wegener's Granulomatosis Etanercept Trial (WGET) and the Rituximab in ANCA-associated Vasculitis (RAVE) trial. His other research efforts relate to the identification of new biomarkers through proteomic approaches, and to the development of clinical trials' outcome measures in rheumatic autoimmune diseases.

Haralampos M. Moutsopoulos, MD, FACP, FRCP is a Professor and Head of the Department of Pathophysiology, Medical School, University of Athens, Greece. He has contributed to current understanding of the clinical aspects, pathogenesis and therapy of autoimmune rheumatic disorders. He is considered a world authority on Sjögren's syndrome (autoimmune epithelitis). His scientific work is extensively cited and he has been presented with numerous national and international awards.

The Editors have extensive experience in the management of the main systemic autoimmune diseases, such as systemic lupus erythematosus, vasculitis and especially Sjögren's syndrome. They havedeveloped many clinical and basic research projects and, in the last 5 years, have published many reports on Sjögren's syndrome and other autoimmune diseases in the leading journals in rheumatology and internal medicine.

Inhalt
Epidemiology.- Genetics and Proteomics.- Immunopathogenesis.- Viruses.- Etiopathogenic role of B-cells.- Oral involvement.- Ocular involvement.- Ear, nose and throat involvement.- Fatigue, fibromyalgia and other general symptoms.- Musculoskeletal involvement.- Non-vasculitic cutaneous involvement.- Vasculitis.- Cardiovascular involvement.- Pulmonary involvement.- Raynaud phenomenon.- Gastrointestinal involvement.- Autoimmune liver involvement.- Pancreatic involvement.- Nephro-urological involvement.- Central nervous system involvement.- Peripheral neuropathy.- Autonomic neuropathy.- Endocrine involvement.- Gynecological and obstetrical complications.- Laboratory abnormalities.- Diagnostic procedures (I).- Diagnostic procedures (II).- Immunological tests.- Classification criteria.- Measurement of chronicity and activity.- Measurement of quality of life.- Association with other autoimmune and rheumatic diseases.- Cancer.- Prognostic factors and survival.- SS in primary care.-Treatment of sicca features.- Treatment of B-cell lymphoma.- Classic immunosuppressive and immunomodulatory drugs.- New immunosuppressive and immunomodulatory drugs.- B-cell targeted therapies.- Other biological therapies.- Experimental therapies.